484654-49-1

Basic information

• Product Name: 2-(4-pyridinyl)Cyclopropanecarboxylic acid
• Synonyms: 2-(4-pyridinyl)Cyclopropanecarboxylic acid;(1R,2S)-2-(pyridin-4-yl)cyclopropanecarboxylic acid;2-(PYRIDIN-4-YL)CYCLOPROPANE-1-CARBOXYLIC ACID
• CAS NO: 484654-49-1
• Molecular Formula: C9H9NO2
• Molecular Weight: 163.17326
• Mol File: 484654-49-1.mol

Chemical Properties

• Boiling Point: 95-105 °C(Press: 0.3 Torr)
• Appearance: /
• Density: 1.327±0.06 g/cm3(Predicted)
• PKA: 3.99±0.11(Predicted)
• CAS DataBase Reference: 2-(4-pyridinyl)Cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-pyridinyl)Cyclopropanecarboxylic acid(484654-49-1)
• EPA Substance Registry System: 2-(4-pyridinyl)Cyclopropanecarboxylic acid(484654-49-1)

Safety Data

• Hazardous Substances Data: 484654-49-1(Hazardous Substances Data)

Usage

Structure

Contains a cyclopropane ring and a pyridine ring

Usage

Commonly used in pharmaceutical research and drug development

Biological activities

Potential use in the treatment of various diseases, including cancer and inflammatory conditions

Function

Acts as a ligand for various receptors and enzymes

Structure optimization

Allows for potential modification and optimization of its pharmacological properties

Importance

An important compound in medicinal chemistry with potential therapeutic applications

Upstream product

• 1120-87-2 4-bromopyridin 
• 84228-93-3 3-(pyridin-4-yl)acrylic acid 
• 372183-81-8 (2E)-N-methoxy-N-methyl-3-(pyridin-4-yl)prop-2-enamide 
• 24489-96-1 ethyl 3-(pyridin-4-yl)prop-2-enoate 
• 5337-79-1 3-(4-pyridinyl)-2-propenoic acid 

Relevant articles and documents

SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF

Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

CYCLOPROPYL AMIDE DERIVATIVES

The present invention relates to certain cyclopropyl amide compounds, pharmaceutical compositions comprising such compounds, and methods of treating cancer, including leukemias and solid tumors, inflammatory diseases, osteoporosis, atherosclerosis, irritable bowel syndrome, and other diseases and medical conditions, with such compounds and pharmaceutical compositions. The present invention also relates to certain cyclopropyl amide compounds for use in inhibiting nicotinamide phosphoribosyltransferase ("NAMPT").

Fragment-based identification of amides derived from trans-2-(pyridin-3-yl) cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Potent, trans-2-(pyridin-3-yl)cyclopropanecarboxamide-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques. Multiple crystal structures were obtained of initial fragment leads, and this structural information was utilized to improve the biochemical and cell-based potency of the associated molecules. Many of the optimized compounds exhibited nanomolar antiproliferative activities against human tumor lines in in vitro cell culture experiments. In a key example, a fragment lead (13, KD = 51 μM) was elaborated into a potent NAMPT inhibitor (39, NAMPT IC 50 = 0.0051 μM, A2780 cell culture IC50 = 0.000 49 μM) which demonstrated encouraging in vivo efficacy in an HT-1080 mouse xenograft tumor model.

APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS

The present invention relates to apoptosis signal-regulating kinase 1 ("ASK1") inhibiting compounds of the formula (I); wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Certain pyrazoline derivatives with kinase inhibitory activity

The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.